Improving theranostics in pancreatic cancer.
Improving theranostics in pancreatic cancer.
复制标题
DOI:
10.1002/jso.24625
复制
发表时间:
2017-07
影响因子:
2.5
通讯作者:
Williams J
中科院分区:
文献类型:
--
作者:
King J;Bouvet M;Singh G;Williams J
Pancreatic cancer is the fourth most deadly cancer in the US, and is expected to be the second most deadly by 2030. The major difficulty in treating pancreatic cancer is the late onset of symptoms. Generally, patients show metastatic disease by the time of diagnosis, with a survival rate of 5% beyond 5 years. In patients without metastatic disease, surgical resection increases 5 year survival rate to 25%. The remaining 75% succumb to undetected metastases. Clearly, improvements to both detection, surgical intervention, and therapeutic strategies will be needed to improve patient outcome in pancreatic cancer. Recent literature has been surveyed and atomic models of new therapeutic appoaches were generated. Here, we focus on the recent progress employing monoclonal antibodies (mAbs) to target pancreatic cancer associated markers, and more specifically on recent chemical and protein engineering efforts to improve the homogeneity, stability, and administration of mAbs to precisely delivery imaging agents and cytotoxins to sites of disease.
登录
查看更多内容
影响因子:
16
作者:
Sablin, EP;Krylova, IN;Ingraham, HA
通讯作者:
Ingraham, HA
DOI:
10.1073/pnas.1112047108
发表时间:
2011-10-11
影响因子:
11.1
作者:
Benod, Cindy;Vinogradova, Maia V.;Sablin, Elena P.
通讯作者:
Sablin, Elena P.
影响因子:
3.7
作者:
de Jesus Cortez F;Suzawa M;Irvy S;Bruning JM;Sablin E;Jacobson MP;Fletterick RJ;Ingraham HA;England PM
通讯作者:
England PM
影响因子:
16
作者:
Botrugno, OA;Fayard, E;Schoonjans, K
通讯作者:
Schoonjans, K
影响因子:
7.5
作者:
Stein, Sokrates;Schoonjans, Kristina
通讯作者:
Schoonjans, Kristina